Aspirin-Induced Asthma

Samter M, Beers RF. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68: 975–83

Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002; 89(5): 474–8

Kasper L, Sladek K, Duplaga M, et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 2003; 58(10): 1064–6

Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002; 57(7): 569–74

Nizankowska E, Bestynska-Krypel A, Cmiel A, et al. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000; 15(5): 863–9

Alonso-Llamazares A, Martinez-Cocera C, Dominguez-Ortega J, et al. Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA). Allergy 2002; 57(7): 632–5

Milewski M, Mastalerz L, Nizankowska E, et al. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 1998 May; 101(5): 581–6

Casadevall J, Ventura P-J, Mullol J, et al. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000; 55: 921–4

Schlumberger HD. Drug-induced pseudo-allergic syndrome as exemplified by acetylsalicylic acid intolerance. Basel: Karger, 1980: 125–203

Nasser SM, Pfister R, Christie PE, et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996; 153(1): 90–6

Hamilos DL, Leung DY, Wood R, et al. Eosinophil infiltration in nonallergic chronic hyperplastic sinusitis with nasal polyposis (CHS/NP) is associated with endothelial VCAM-1 upregulation and expression of TNF-alpha. Am J Respir Cell Mol Biol 1996; 15(4): 443–50

Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101(4): 834–46

Szczeklik A, Sladek K, Dworski R, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1996; 154 (6 Pt 1): 1608–14

Mastalerz L, Sanak M, Szczeklik A. Serum interleukin-5 in aspirin-induced asthma. Clin Exp Allergy 2001; 31(7): 1036–40

Sanak M, Bazan-Soch S, Szczeklik A. Leukotriene C4 synthase expression in blood eosinophils of patients with asthma. Eur Respir J 1998; 12 Suppl. 28: 373s

Nakagawa H, Yoshida S, Nakabayashi M, et al. Possible relevance of virus infection for development of analgesic idiosyncrasy. Respiration 2001; 68(4): 422–4

Szczeklik A, Nizankowska E, Serafin A, et al. Autoimmune phenomena in bronchial asthma with special reference to aspirin intolerance. Am J Respir Crit Care Med 1995; 152 (6 Pt 1): 1753–6

Lassalle P, Delneste Y, Gosset P, et al. T and B cell immune response to a 55-kDa endothelial cell-derived antigen in severe asthma. Eur J Immunol 1993; 23(4): 796–803

Szczeklik A, Musial J, Pulka G. Autoimmune vasculitis and aortic stenosis in aspirin-induced asthma (AIA). Allergy 1997; 52(3): 352–4

Dekker JW, Nizankowska E, Schmitz-Schumann M, et al. Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes. Clin Exp Allergy 1997; 27(5): 574–7

Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988; 18(1): 15–20

Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc Natl Acad Sci U S A 2002; 99: 13926–31

Pang L. COX-2 expression in asthmatic airways: the story so far. Thorax 2003; 56: 335–6

Schwab JM, Schluesener HJ, Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol? Lancet 2003; 361(9362): 981–2

Holtzman MJ. Arachidonic acid metabolism: implications of biological chemistry for lung function and disease. Am Rev Respir Dis 1991; 143(1): 188–203

Holgate ST, Burns GB, Robinson C, et al. Anaphylactic- and calcium-dependent generation of prostaglandin D2 (PGD2), thromboxane B2, and other cyclooxygenase products of arachidonic acid by dispersed human lung cells and relationship to histamine release. J Immunol 1984; 133(4): 2138–44

Churchill L, Chilton FH, Resau JH, et al. Cyclooxygenase metabolism of endogenous arachidonic acid by cultured human tracheal epithelial cells. Am Rev Respir Dis 1989; 140(2): 449–59

Pang L, Knox AJ. Effect of interleukin-1 beta, tumour necrosis factor alpha and interferon gamma on the induction of cyclooxygenase-2 in cultured human airway smooth muscle cells. Br J Pharmacol 1997; 121(3): 579–87

Belvisi MG, Saunders MA, Haddad el-B, et al. Induction of cyclooxygenase-2 by cytokines in human cultured airway smooth muscle cells: novel inflammatory role of this cell type. Br J Pharmacol 1997; 120(5): 910–6

Pang L, Pitt A, Petkova D, et al. The COX-l/COX-2 balance in asthma. Clin Exp Allergy 1998; 28(9): 1050–8

Kuehl Jr FA, Dougherty HW, Ham EA. Interactions between prostaglandins and leukotrienes. Biochem Pharmacol 1984; 33(1): 1–5

Christman BW, Christman JW, Dworski R, et al. Prostaglandin E2 limits arachidonic acid availability and inhibits leukotriene B4 synthesis in rat alveolar macrophages by a nonphospholipase A2 mechanism. J Immunol 1993; 151(4): 2096–104

An S, Goetzl EJ. Lipid mediators of hypersensitivity and inflammation. In: Middleton E, Ellis EF, Adkinson NF, et al., editors. Allergy: principles and practice. St Louis (MO): Mosby, 1998: 168–82

Kahn RM, Okanlami OA, Jacoby DB, et al. Viral infection induces dependence of neuronal M2 muscarinic receptors on cyclooxygenase in guinea pig lung. J Clin Invest 1996; 98(2): 299–307

Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996; 153(2): 572–5

Murray JJ, Mullins MD, Knapp HR, et al. Regulation of the immune response by eicosanoids: pharmacology and clinical effects of prostaglandin E in aspirin-sensitive syndromes. Am J Ther 1995; 2(10): 739–48

Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. BMJ 1975; 1: 67–9

Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990; 3(5): 588–93

Picado C. Aspirin-intolerant asthma: role of cyclooxygenase enzymes. Allergy 2002; 57 Suppl. 72: 58–60

Obase Y, Shimoda T, Tomari SY, et al. Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. Chest 2002; 121(1): 143–50

Dahlen B, Kumlin M, Margolskee D, et al. The leukotrienereceptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993 Jul; 6(7): 1018–26

Kowalski M, Pawliczak R, Wozniak J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000; 161: 391–8

Sanak M, Levy B, Clish C, et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000; 16: 44–9

Schäfer D, Schmid M, Göde U, et al. Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur Respir J 1999; 13: 638–46

Sousa A, Pfister R, Christie PE, et al. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax 1997; 52(11): 940–5

Picado C, Bioque G, Roca-Ferrer J, et al. Nuclear factorkappaB activity is down-regulated in nasal polyps from aspirin-sensitive asthmatics. Allergy 2003; 58(2): 122–6

Picado C, Fernandez-Morata J, Juan M,etal. Cyclo-oxygenase-2 mRNA is downexpressed in nasal polyps from aspirinsensitive asthmatics. Am J Respir Crit Care Med 1999; 160: 291–6

Bennett A. The importance of COX-2 inhibition for aspirin induced asthma. Thorax 2000; 55 Suppl. 2: S54–6

Szczeklik A, Nizankowska E, Dworski R. Choline magnesium trisalicylate in patients with aspirin-induced asthma. Eur Respir J 1990 May; 3(5): 535–9

Szczeklik A, Nizankowska E, Bochenek G, et al. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001; 31(2): 219–25

Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001; 108(1): 47–51

Martin-Garcia C, Hinojosa M, Berges P, et al. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002; 121(6): 1812–7

Stevenson DD, Lewis RA. Proposed mechanisms of aspirin sensitivity reactions. J Allergy Clin Immunol 1987; 80(6): 788–90

Higashi N, Taniguchi M, Mita H, et al. A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. Clin Exp Allergy 2002; 32(10): 1484–90

Fischer AR, Rosenberg MA, Lilly CM, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994; 94 (6 Pt 1): 1046–56

O’Sullivan S, Dahlen B, Dahlen SE, et al. Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 betaprostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol 1996; 98(2): 421–32

Mita H, Endoh S, Kudoh M, et al. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy 2001; 56(11): 1061–7

Bochenek G, Nagraba K, Nizankowska E, et al. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003; 111(4): 743–9

Pavord ID, Tattersfield AE. Bronchoprotective role for endogenous prostaglandin E2. Lancet 1995; 345(8947): 436–8

Bianco S, Robuschi M, Damonte C, et al. Bronchial response to nonsteroidal anti-inflammatory drugs in asthmatic patients. Prog Biochem Pharmacol 1985; 20: 132–42

Crimi N, Palermo F, Polosa R, et al. Effect of indomethacin on adenosine-induced bronchoconstriction. J Allergy Clin Immunol 1989; 83(5): 921–5

Field PI, Simmul R, Bell SC, et al. Evidence for opioid modulation and generation of prostaglandins in sulphur dioxide (SO)2-induced bronchoconstriction. Thorax 1996; 51(2): 159–63

Fish JE, Ankin MG, Adkinson Jr NF, et al. Indomethacin modification of immediate-type immunologic airway responses in allergic asthmatic and non-asthmatic subjects: evidence for altered arachidonic acid metabolism in asthma. Am Rev Respir Dis 1981; 123(6): 609–14

Curzen N, Rafferty P, Holgate ST. Effects of a cyclo-oxygenase inhibitor, flurbiprofen, and an H1 histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man. Thorax 1987; 42(12): 946–52

O’Connor BJ, Barnes PJ, Chung KF. Inhibition of sodium metabisulphite induced bronchoconstriction by frusemide in asthma: role of cyclooxygenase products. Thorax 1994; 49(4): 307–11

Phillips GD, Holgate ST. The effect of oral terfenadine alone and in combination with flurbiprofen on the bronchoconstrictor response to inhaled adenosine 5′-monophosphate in nonatopic asthma. Am Rev Respir Dis 1989; 139(2): 463–9

Wang M, Wisniewski A, Pavord I, et al. Comparison of three inhaled non-steroidal anti-inflammatory drugs on the airway response to sodium metabisulphite and adenosine 5′-monophosphate challenge in asthma. Thorax 1996; 51(8): 799–804

Sestini P, Refini RM, Pieroni MG, et al. Protective effect of inhaled lysine acetylsalicylate on allergen-induced early and late asthmatic reactions. J Allergy Clin Immunol 1997; 100(1): 71–7

Mitchell JA, Belvisi MG. Too many COX (cyclo-oxygenase) spoil the broth: aspirin-sensitive asthma and 5-lipoxygenase. Thorax 1997; 52(11): 933–5

Mitchell JA, Saunders M, Barnes PJ, et al. Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol Pharmacol 1997; 51(6): 907–12

Holtzman MJ, Turk J, Shornick LP. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J Biol Chem 1992; 267(30): 21438–45

Claria D, Sherhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A 1995; 92: 9475–9

Dahlen B, Dahlen SE. Leukotrienes as mediators of airway obstruction and inflammation in asthma. Clin Exp Allergy 1995; 25 Suppl. 2: 50–4

Pauls JD, Simon RA, Daffern PJ, et al. Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 2000 Jul; 85(1): 40–5

Antczak A, Montuschi P, Kharitonov S, et al. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002; 166(3): 301–6

Picado C, Ramis I, Rosello J, et al. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis 1992; 145(1): 65–9

Ziroli NE, Na H, Chow JM, et al. Aspirin-sensitive versus nonaspirin-sensitive nasal polyp patients: analysis of leukotrienes/ Fas and Fas-ligand expression. Otolaryngol Head Neck Surg 2002; 126(2): 141–6

Celik G, Bavbek S, Misirligil Z, et al. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E (2) on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients. Clin Exp Allergy 2001; 31(10): 1615–22

Penrose JF, Spector J, Baldasaro M, et al. Molecular cloning of the gene for human leukotriene C4 synthase: organization, nucleotide sequence, and chromosomal localization to 5q 35. J Biol Chem 1996; 271(19): 11356–61

Tornhamre S, Ehnhage A, Kolbeck KG, et al. Uncoupled regulation of leukotriene C4 synthase in platelets from aspirinintolerant asthmatics and healthy volunteers after aspirin treatment. Clin Exp Allergy 2002; 32(11): 1566–73

Sanak M, Simon H-U, Szczerklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350: 1599–60

Szczeklik A, Sanak M, Nizankowska E, et al. Leukotriene C4 synthase genetic polymorphism directs urinary cysteinylleukotriene response to aspirin-challenge in asthma [abstract]. Allergy 1998; 53 Suppl. 43: 61

Asano K, Shiomi T, Hasegawa N, et al. Leukotriene C4 synthase gene A (−444)C polymorphism and clinical response to a CYS-LT (1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002 Oct; 12(7): 565–70

Sanak M, Szczeklik A. Genetics of aspirin induced asthma. Thorax 2000; 55 Suppl. 2: S45–7

Sampson AP, Siddiqui S, Buchanan D, et al. Variant LTC (4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55 Suppl. 2: S28–31

Kawagishi Y, Mita H, Taniguchi M, et al. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002; 109(6): 936–42

Arm JP, O’Hickey SP, Spur BW, et al. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirininduced asthma. Am Rev Respir Dis 1989; 140(1): 148–53

Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirinsensitive rhinosinusitis. N Engl J Med 2002; 347(19): 1493–9

Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and proresolution. Prostaglandins Other Lipid Mediat 2002; 68-69: 433–55

Levy BD, Serhan CN. Polyisoprenyl phosphates: natural antiinflammatory lipid signals. Cell Mol Life Sci 2002; 59(5): 729–41

Evsyukova HV. Aspirin-sensitive asthma due to diffuse neuroendocrine system pathology. Neuroendocrinol Lett 2002; 23(4): 281–5

Evsiukova EV, Khavinson VK, Trofimov VI, et al. Epifamine efficacy in aspirin bronchial asthma. Klin Med (Mosk) 2001; 79(9): 61–4

Tattersfield A, Knox A, Britton J, et al. Asthma. Lancet 2002; 360: 1313–22

Angus RM. Inhaled corticosteroids (budesonide): the cornerstone of asthma therapy: what are the options? Pulm Pharmacol Ther 2002; 15(6): 479–84

Riccioni G, Santilli F, D’Orazio N, et al. The role of antileukotrienes in the treatment of asthma. Int J Immunopathol Pharmacol 2002; 15(3): 171–82

Dahlen SE, Malmström K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist. Am J Respir Crit Care Med 2002; 165: 9–14

Dahlen B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157 (4 Pt 1): 1187–94

Orea SM, Flores SG, Machado CF, et al. Aspirin induced asthma, urinary leukotriene E4 and zafirlukast. Rev Alerg Mex 2002; 49(2): 52–6

Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SKª 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144(4): 957–8

Yamamoto H, Nagata M, Kuramitsu K, et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994; 150(1): 254–7

Nasser SM, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 1994; 49(8): 749–56

Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148 (6 Pt 1): 1447–51

Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 2002; 32(10): 1491–6

Pauls JD, Simon RA, Daffern PJ, et al. Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 2000 Jul; 85(1): 40–5

Volkman JA, Pontikes PJ. Leukotriene modifiers to prevent aspirin-provoked respiratory reactions in asthmatics. Ann Pharmacother 2002; 36(9): 1457–61

Tang MBY, Yosipovitch G. Acute Churg-Strauss syndrome in an asthmatic patient receiving montelukast therapy. Arch Dermatol 2003; 139(6): 715–8

Guilpain P, Viallard JF, Lagarde P, et al. Churg-Strauss syndrome in two patients receiving montelukast. Rheumatology (Oxford) 2002; 41(5): 535–9

Jamaleddine G, Diab K, Tabbarah Z, et al. Leukotriene antagonists and the Churg-Strauss syndrome. Semin Arthritis Rheum 2002; 31(4): 218–27

Garcia-Marcos L, Schuster A. Antileukotrienes in asthma: present] situation. Expert Opin Pharmacother 2001; 2(3): 441–66

Katsura T, Yoshida F, Takinishi Y. The Churg-Strauss syndrome after pranlukast treatment in a patient not receiving corticosteroids. Ann Intern Med 2003; 139(5): 386–7

Kobayashi S, Ishizuka S, Tamura N, et al. Churg-Strauss syndrome in a patient receiving pranlukast. Clin Rheumatol 2003 Dec; 22(6): 491–2

Bochenek G, Swierczynska M, Nizankowska-Mogilnicka E, et al. Tolerability of asacard: controlled-release aspirin and aspirin-induced asthma. Pol Arch Med Wewn 2002; 107(3): 249–56

Karakaya G, Kalyoncu AF. Paracetamol and asthma. Expert Opin Pharmacother 2003; 4(1): 13–21

Szczeklik A, Nizankowska E, Mastalerz L, et al. Analgesics and asthma. Am J Ther 2002; 9(3): 233–43

Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 2002; 46(8): 2201–6

Bingham III CO. Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis. Cleve Clin J Med 2002; 69 Suppl. 1: SI5–12

Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111(1): 180–6

Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003; 90(3): 338–41

Gosepath J, Schafer D, Mann WJ. Aspirin sensitivity: long term follow-up after up to 3 years of adaptive desensitization using a maintenance dose of 100mg of aspirin a day. Laryngorhinootologie 2002; 81(10): 732–8

Juergens UR, Christiansen SC, Stevenson DD, et al. Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol 1995; 96(2): 148–56

Nasser SM, Patel M, Bell GS, et al. The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. Am J Respir Crit Care Med 1995; 151(5): 1326–30

Amayasu H, Nakabayashi M, Akahori K, et al. Cromolyn sodium suppresses eosinophilic inflammation in patients with aspirin-intolerant asthma. Ann Allergy Asthma Immunol 2001; 87(2): 146–50

Szczeklik A, Dworski R, Mastalerz L, et al. Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism. Am J Respir Crit Care Med 1998; 158(4): 1168–72

Taylor IK, O’Shaughnessy KM, Choudry NB, et al. A comparative study in atopic subjects with asthma of the effects of salmeterol and salbutamol on allergen-induced bronchoconstriction, increase in airway reactivity, and increase in urinary leukotriene E4 excretion. J Allergy Clin Immunol 1992; 89(2): 575–83

Tries S, Neupert W, Laufer S. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 2002; 51(3): 135–43

Gray PA, Warner TD, Vojnovic I, etal. Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors. Br J Pharmacol 2002; 137(7): 1031–8